

DYNAVAX TECHNOLOGIES CORP

Form 8-K

August 06, 2004

Table of Contents

**SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 5, 2004

DYNAVAX TECHNOLOGIES CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

Commission File Number: 000-1029142

Delaware

(State or Other Jurisdiction of
Incorporation)

33-0728374

(I.R.S. Employer Identification No.)

717 Potter Street, Suite 100

Berkeley, CA 94710-2722

(Address of Principal Executive Offices including zip code)

(510) 848-5100

(Registrant's Telephone Number, Including Area Code)

TABLE OF CONTENTS

Item 7. Financial Statements and Exhibits.

Item 12. Results of Operations and Financial Condition.

SIGNATURES

EXHIBIT 99.1

Table of Contents

Item 7. Financial Statements and Exhibits.

c. Exhibits

| <u>Exhibit No.</u> | <u>Description</u> |
|---------------------------|--|
| 99.1 | Press release of Dynavax Technologies Corporation, dated August 5, 2004. |

Item 12. Results of Operations and Financial Condition.

On August 5, 2004, the Company issued a press release relating to the Company's earnings for the second quarter of fiscal year 2004. A copy of the press release is attached as Exhibit 99.1.

The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 12 and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DYNAVAX TECHNOLOGIES
CORPORATION

Date: August 5, 2004

By: /s/ Dino Dina
Dino Dina, M.D.
President, Chief Executive Officer and
Acting Chief Financial Officer

3